Market Cap 753.10M
Revenue (ttm) 100.25M
Net Income (ttm) -73.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -73.02%
Debt to Equity Ratio 0.00
Volume 1,233,700
Avg Vol 924,096
Day's Range N/A - N/A
Shares Out 44.56M
Stochastic %K 56%
Beta 3.04
Analysts Strong Sell
Price Target $19.73

Company Profile

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin with...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 427 7785
Address:
11 Hughes, Irvine, United States
deepthinker
deepthinker Jul. 17 at 1:11 PM
$TRIB Perceptive has left Gillard in place coming on three years now. Why? Because he’s (apparently) progressed the CGM to near the finish line, which is the main thing they care about. Perceptive is always looking for extra base hits, and CGM’s qualify. The model is $BBNX, which is one of several companies eating Insulet’s crumbs, but those are some pretty big crumbs. There are Dexcom/Abbott crumbs out there, as well.
0 · Reply
XI_JINPING_BOUGHT_BABA
XI_JINPING_BOUGHT_BABA Jul. 15 at 1:22 AM
$MODD I am long MODD, but it is not a guaranteed win. Beta Bionic’s $BBNX Mint pump is the pivot, but better, and targeted for commercial launch q2 2027, only 6-9 months after Pivot. If Pivot isn’t a commercial hit within the next 6 months, $MODD will lose, and it is a clear sell. Hold me honest to my word - this stock is down tremendously or up tremendously by EOY, with no inbetween.
2 · Reply
JFDI
JFDI Jun. 28 at 11:26 PM
$BBNX mid range but on lsit
0 · Reply
ap20
ap20 Jun. 25 at 3:57 PM
$BBNX Congrats longs. No position, unfortunately.
0 · Reply
LinzonTard
LinzonTard Jun. 20 at 10:12 PM
$PODD I’m thinking about investing in the pump/CGM space and the field is getting crowded. I think $BBNX wins with simplicity for patients and doctors. It learns dosing itself and meals are not carbohydrate counting, but easy Bolus dosing based on historical learned meals: less, same, more than usual. This will win market share.
1 · Reply
topstockalerts
topstockalerts Jun. 4 at 10:13 PM
$BBNX the market seems reluctant to let this fade.
0 · Reply
diastud
diastud Jun. 2 at 1:14 AM
$BBNX volume is slowly increasing. This will be 2-3x soon
1 · Reply
ThePatch
ThePatch May. 28 at 7:50 PM
$BBNX has anyone dug into this compares to the Twiist pump?
0 · Reply
1trendingup
1trendingup May. 22 at 2:13 AM
$BBNX https://www.globenewswire.com/news-release/2026/05/21/3299712/0/en/beta-bionics-updates-commercialization-timeline-expectations-for-mint-its-patch-pump-in-development.html No wonder what this is up the last few days…
0 · Reply
deepthinker
deepthinker May. 18 at 3:32 PM
$MODD $BBNX has a patch pump coming in late 2027. I wonder if they could slap the iLet AID on Pivot, and how long that would take to get through the FDA?
1 · Reply
Latest News on BBNX
Beta Bionics price target raised to $22 from $18 at Truist

2026-07-13T13:50:36.000Z - 4 days ago

Beta Bionics price target raised to $22 from $18 at Truist


Beta Bionics management to meet with Piper Sandler

2026-06-03T20:55:26.000Z - 6 weeks ago

Beta Bionics management to meet with Piper Sandler


Beta Bionics price target raised to $13 from $11 at BofA

2026-05-22T11:58:04.000Z - 2 months ago

Beta Bionics price target raised to $13 from $11 at BofA


Beta Bionics Transcript: AGM 2026

May 21, 2026, 5:00 PM EDT - 2 months ago

Beta Bionics Transcript: AGM 2026


Beta Bionics price target lowered to $11 from $23 at BofA

2026-05-18T12:00:44.000Z - 2 months ago

Beta Bionics price target lowered to $11 from $23 at BofA


Beta Bionics price target lowered to $20 from $22 at Stifel

2026-04-22T11:50:58.000Z - 3 months ago

Beta Bionics price target lowered to $20 from $22 at Stifel


Beta Bionics reports Q1 EPS (49c), consensus (45c)

2026-04-21T20:31:34.000Z - 3 months ago

Beta Bionics reports Q1 EPS (49c), consensus (45c)


Beta Bionics Earnings Call Transcript: Q1 2026

Apr 21, 2026, 4:30 PM EDT - 3 months ago

Beta Bionics Earnings Call Transcript: Q1 2026


Beta Bionics Earnings release: Q1 2026

Apr 21, 2026, 4:30 PM EDT - 3 months ago

Beta Bionics Earnings release: Q1 2026


Beta Bionics Slides: Q1 2026

Apr 21, 2026, 4:30 PM EDT - 3 months ago

Beta Bionics Slides: Q1 2026


Beta Bionics Quarterly report: Q1 2026

Apr 21, 2026, 4:30 PM EDT - 3 months ago

Beta Bionics Quarterly report: Q1 2026


Beta Bionics sees FY26 revenue $131M-$136M, consensus $132.58M

2026-04-21T20:28:56.000Z - 3 months ago

Beta Bionics sees FY26 revenue $131M-$136M, consensus $132.58M


Beta Bionics price target lowered to $18 from $25 at Truist

2026-04-15T12:36:49.000Z - 3 months ago

Beta Bionics price target lowered to $18 from $25 at Truist


Beta Bionics, Inc. Investigated by the Portnoy Law Firm

Apr 14, 2026, 9:00 AM EDT - 3 months ago

Beta Bionics, Inc. Investigated by the Portnoy Law Firm


Beta Bionics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Beta Bionics Proxy statement: Proxy filing


Beta Bionics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Beta Bionics Proxy statement: Proxy filing


Beta Bionics pullback an ‘overreaction,’ says Lake Street

2026-03-24T12:46:35.000Z - 4 months ago

Beta Bionics pullback an ‘overreaction,’ says Lake Street


Beta Bionics management to meet virtually with Lake Street

2026-03-13T15:00:31.000Z - 4 months ago

Beta Bionics management to meet virtually with Lake Street


Beta Bionics files automatic mixed securities shelf

2026-02-24T22:20:44.000Z - 5 months ago

Beta Bionics files automatic mixed securities shelf


Beta Bionics price target lowered to $14 from $28 at Baird

2026-02-18T12:50:59.000Z - 5 months ago

Beta Bionics price target lowered to $14 from $28 at Baird


Beta Bionics price target lowered to $22 from $25 at Stifel

2026-02-18T11:51:17.000Z - 5 months ago

Beta Bionics price target lowered to $22 from $25 at Stifel


Beta Bionics sees FY26 revenue $130M-$135M, consensus $132.68M

2026-02-17T21:55:25.000Z - 5 months ago

Beta Bionics sees FY26 revenue $130M-$135M, consensus $132.68M


Beta Bionics reports Q4 EPS (30c), consensus (38c)

2026-02-17T21:50:27.000Z - 5 months ago

Beta Bionics reports Q4 EPS (30c), consensus (38c)


Beta Bionics Earnings Call Transcript: Q4 2025

Feb 17, 2026, 4:30 PM EST - 5 months ago

Beta Bionics Earnings Call Transcript: Q4 2025


Beta Bionics Annual report: Q4 2025

Feb 17, 2026, 4:30 PM EST - 5 months ago

Beta Bionics Annual report: Q4 2025


Beta Bionics Earnings release: Q4 2025

Feb 17, 2026, 4:30 PM EST - 5 months ago

Beta Bionics Earnings release: Q4 2025


Beta Bionics Slides: Q4 2025

Feb 17, 2026, 4:30 PM EST - 5 months ago

Beta Bionics Slides: Q4 2025


deepthinker
deepthinker Jul. 17 at 1:11 PM
$TRIB Perceptive has left Gillard in place coming on three years now. Why? Because he’s (apparently) progressed the CGM to near the finish line, which is the main thing they care about. Perceptive is always looking for extra base hits, and CGM’s qualify. The model is $BBNX, which is one of several companies eating Insulet’s crumbs, but those are some pretty big crumbs. There are Dexcom/Abbott crumbs out there, as well.
0 · Reply
XI_JINPING_BOUGHT_BABA
XI_JINPING_BOUGHT_BABA Jul. 15 at 1:22 AM
$MODD I am long MODD, but it is not a guaranteed win. Beta Bionic’s $BBNX Mint pump is the pivot, but better, and targeted for commercial launch q2 2027, only 6-9 months after Pivot. If Pivot isn’t a commercial hit within the next 6 months, $MODD will lose, and it is a clear sell. Hold me honest to my word - this stock is down tremendously or up tremendously by EOY, with no inbetween.
2 · Reply
JFDI
JFDI Jun. 28 at 11:26 PM
$BBNX mid range but on lsit
0 · Reply
ap20
ap20 Jun. 25 at 3:57 PM
$BBNX Congrats longs. No position, unfortunately.
0 · Reply
LinzonTard
LinzonTard Jun. 20 at 10:12 PM
$PODD I’m thinking about investing in the pump/CGM space and the field is getting crowded. I think $BBNX wins with simplicity for patients and doctors. It learns dosing itself and meals are not carbohydrate counting, but easy Bolus dosing based on historical learned meals: less, same, more than usual. This will win market share.
1 · Reply
topstockalerts
topstockalerts Jun. 4 at 10:13 PM
$BBNX the market seems reluctant to let this fade.
0 · Reply
diastud
diastud Jun. 2 at 1:14 AM
$BBNX volume is slowly increasing. This will be 2-3x soon
1 · Reply
ThePatch
ThePatch May. 28 at 7:50 PM
$BBNX has anyone dug into this compares to the Twiist pump?
0 · Reply
1trendingup
1trendingup May. 22 at 2:13 AM
$BBNX https://www.globenewswire.com/news-release/2026/05/21/3299712/0/en/beta-bionics-updates-commercialization-timeline-expectations-for-mint-its-patch-pump-in-development.html No wonder what this is up the last few days…
0 · Reply
deepthinker
deepthinker May. 18 at 3:32 PM
$MODD $BBNX has a patch pump coming in late 2027. I wonder if they could slap the iLet AID on Pivot, and how long that would take to get through the FDA?
1 · Reply
NVDAMillionaire
NVDAMillionaire May. 14 at 2:33 PM
$BBNX Really good write-up that perfectly summarizes BBNX's present situation. So if you want to bring your BBNX knowledge up to date or just discover BBNX, this is required reading. https://everyticker.com/quote/BBNX/analysis/pharmacy-channel-inflection-how-beta-bionics-is-building-a-saas-like-diabetes-franchise-nasdaq-bbnx
0 · Reply
deepthinker
deepthinker May. 13 at 2:18 PM
$BBNX So, they had about $200 million end of Q1. That’s about 8 quarters at current burn. So, they’ll be out of money Q1 of 2028 unless they dilute. The growth is still good, considering they have no patch pump, but I’m not clear what’s going to happen when they burn through their stash.
2 · Reply
MarketBeat
MarketBeat May. 13 at 6:06 AM
https://marketbeat.com/a/8651341/ $BBNX Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans
0 · Reply
deepthinker
deepthinker May. 10 at 3:18 PM
$BBNX I would be surprised if we don’t get a bid given the crushed stock price here. Easy to consolidate and clean up the SG&A. Toss the iLet in another bag. Too many players in this space.
0 · Reply
deepthinker
deepthinker May. 7 at 1:45 PM
$BBNX My hunch is this company could be in play here. Tandem has supply and IP issues. DEKA is private. Minimed is still owned by Medtronic.
0 · Reply
ScoutWatch12
ScoutWatch12 May. 7 at 2:18 AM
$BBNX as a T1D using this pump - we aren’t wrong, just early. (It’s the same thing!! I know) patience. This is unbelievably ahead of tandem, omnipod, twist, and the unmentionables. They must figure out how to get the doctors onboard. The pump castrates the endocrinologist and they don’t like that at all.
2 · Reply
deepthinker
deepthinker May. 6 at 7:32 PM
$PODD Who’s likely not in play: Tandem, DEKA, MiniMed. Who’s in play: $BBNX
0 · Reply
deepthinker
deepthinker May. 6 at 7:01 PM
$BBNX Given Insulet’s slowing growth arc, they may look to buy growth.
0 · Reply
firewulf
firewulf May. 5 at 11:39 PM
$BBNX remember when the CFO sold 30 percent of his stock at $30. Love the comments defending this company though
0 · Reply
deepthinker
deepthinker May. 2 at 3:42 PM
$BBNX I don’t quite understand the strategy here. They’re going to try and build revenues even if it drains cash to zero in 7 quarters? What happens then? In my opinion, there are just too many companies in this space. It’s causing spend to get out of control. The first victim will be this company. They should reverse course and go for profitability rather than growth.
4 · Reply
BillionerOfKing
BillionerOfKing May. 2 at 2:30 AM
$BBNX Current Stock Price: $10.27 Contracts to trade: $10.0 BBNX May 15 2026 Call Entry: $0.55 Exit: $0.91 ROI: 66% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Arcides
Arcides Apr. 28 at 7:26 PM
$BBNX medical devices stocks are trash...
1 · Reply